Fluconazole for oropharyngeal candidiasis in anti-HIV positive haemophiliacs.
Candidiasis of the oropharynx and oesophagus is one of the most common problems encountered in patients with HIV disease. Fluconazole is a bis-triazole antifungal agent with a long serum half-life. Sixteen anti-HIV positive patients (15 haemophiliacs and one blood transfusion recipient) with a clinical diagnosis of oropharyngeal candidiasis were treated with 50 mg fluconazole daily for 14-28 days and then either 150 mg fluconazole or placebo weekly for 6 months in a prophylactic phase. Clinical cure occurred in all patients, and mycological cure occurred in 13/16 (81%) patients. In the prophylactic phase, there were 2/5 (40%) relapses in the placebo arm compared with 1/8 (12.5%) in the fluconazole arm, but this was not statistically significant by Fisher's one-sided exact test (P = 0.31). It is concluded that fluconazole is an effective treatment of oropharyngeal candidiasis and has potential for prophylactic use.
Lim
S G
SG
Haemophilia Centre, Royal Free Hospital School of Medicine London, UK.
Lee
C A
CA
Hales
M
M
O'Doherty
M
M
Winter
M
M
Kernoff
P B
PB
D000293:Adolescent; D000328:Adult; D000368:Aged; D002177:Candidiasis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D002180:Candidiasis, Oral / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D002648:Child; D004311:Double-Blind Method; D005260:Female; D015725:Fluconazole / Q000009:adverse effects / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications*; D006467:Hemophilia A / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010608:Pharyngeal Diseases / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D012008:Recurrence
D015725:Fluconazole